A closer look at CDC16 (CDC16Hs): A potential drug target and biomarker
A closer look at CDC16 (CDC16Hs): A potential drug target and biomarker
Introduction
The protein encoded by the gene CDC16 (CDC16Hs) has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This protein plays a crucial role in the development and maintenance of tissues and organs, making it an attractive target for the development of new treatments. In this article, we will provide an in-depth analysis of CDC16, its potential drug target status, and its potential as a biomarker for various diseases.
CDC16: Structure and Function
CDC16 is a 21-kDa transmembrane protein that is expressed in various tissues and organs, including heart, lungs, liver, and brain. It is composed of a cytoplasmic tail and a transmembrane region that contains a N-terminal domain, a central transmembrane domain , and a C-terminal domain. The cytoplasmic tail of CDC16 is composed of a variable region that includes a unique GXXGXXG repeat and a C-terminal region that contains a T-type transmembrane domain.
CDC16 is involved in various cellular processes, including cell adhesion, migration, and signaling. It is a key regulator of the Wnt signaling pathway, which is involved in the development and maintenance of tissues and organs. Wnt signaling is a complex process that involves the interaction of various proteins, including CDC16, with the Wnt receptor, which is essential for the development and maintenance of tissues and organs.
In addition to its role in the Wnt signaling pathway, CDC16 is also involved in the regulation of cell adhesion and migration. It is a critical regulator of the cadherin-based adhesion molecule, which is involved in tissue-cell adhesion and is a key factor in the development and maintenance of tissues and organs. CDC16 has also been shown to play a role in the regulation of cell migration, including the migration of cancer cells.
CDC16 as a Potential Drug Target
CDC16's involvement in various cellular processes makes it an attractive target for the development of new treatments. The identification of CDC16 as a potential drug target is based on several factors, including its involvement in the regulation of cell adhesion, migration, and signaling, as well as its unique structure and function.
One of the main reasons why CDC16 is considered a potential drug target is its involvement in the regulation of cell adhesion. Cancer cells often have the ability to migrate and invade surrounding tissues, which is a critical step in the development and progression of cancer. Regulation of cell adhesion is critical for the maintenance of tissue homeostasis and is a key factor in the development and progression of cancer.
CDC16 has been shown to play a role in the regulation of cell adhesion by regulating the cadherin-based adhesion molecule. This molecule is composed of two transmembrane domains: a N-terminal domain that contains a critical region for the interaction with CDC16, and a C-terminal domain that contains a unique GXXGXXG repeat. The GXXGXXG repeat is a key region that interacts with CDC16 and is involved in the regulation of cell adhesion.
Another potential mechanism by which CDC16 may contribute to the development and progression of cancer is its involvement in the regulation of cell migration. Cell migration is a critical process that is involved in
Protein Name: Cell Division Cycle 16
Functions: Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains
The "CDC16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC16 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2
